Psyence Biomedical Ltd. Files 6-K with Financial Instrument Details

Ticker: PBMWW · Form: 6-K · Filed: Jan 23, 2025 · CIK: 1985062

Sentiment: neutral

Topics: financial-instruments, warrants, convertible-debt

TL;DR

Psyence Biomedical's 6-K shows warrants and convertible notes outstanding as of Sept 30, 2024.

AI Summary

Psyence Biomedical Ltd. filed a 6-K report for the period ending September 30, 2024. The filing includes details on various financial instruments such as warrants with exercise prices of $2.50 and $862.50, private warrants, and unsecured convertible promissory notes. The company is incorporated in A6 and its fiscal year ends on March 31.

Why It Matters

This filing provides investors with updated information on the company's capital structure and potential future dilution from outstanding warrants and convertible notes.

Risk Assessment

Risk Level: medium — The presence of convertible notes and warrants introduces potential dilution risk for existing shareholders.

Key Players & Entities

FAQ

What is the reporting period for this 6-K filing?

The conformed period of report is for the period ending September 30, 2024.

What types of financial instruments are mentioned in the filing?

The filing mentions warrants with exercise prices of $2.50 and $862.50, private warrants, public warrants, and unsecured convertible promissory notes.

When was this 6-K filing submitted?

The filing was submitted on January 23, 2025.

What is Psyence Biomedical Ltd.'s fiscal year end?

Psyence Biomedical Ltd.'s fiscal year ends on March 31.

What is the company's business address?

The business address is 121 Richmond Street West, Penthouse, Suite 1300, Toronto, A6, M5H 2K1.

Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-01-23 16:01:56

Filing Documents

From the Filing

Psyence Biomedical Ltd._2024-09-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THESECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-41937 Psyence Biomedical Ltd. (Translation of registrant's name into English) 121 Richmond Street West Penthouse Suite 1300 Toronto, Ontario M5H 2K1 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. X Form 20-F Form 40-F Explanatory Note Psyence Biomedical Ltd. (the "Company") is filing this Current Report on Form 6-K to (i) file its unaudited interim consolidated financial statements for the three and six months ended September 30, 2024 and 2023 (the "Interim Financial Statements"), along with its corresponding Management's Discussion and Analysis, and (ii) its updated audited consolidated financial statements for the fiscal years ended March 31, 2024, and March 31, 2023 (the "Updated Financial Statements"). The Updated Financial Statements reflect adjustments made solely to account for the Company's previously announced reverse stock split, which became effective on November 26, 2024. The reverse stock split was implemented at a ratio of 75-to-1, and all share and per-share amounts in the Updated Financial Statements have been retroactively adjusted to reflect this change for all periods presented. No changes were made to the Management's Discussion and Analysis related to the audited condensed financial statements for the years ended March 31, 2024 and 2023. Other than the retroactive adjustments related to the reverse stock split and certain updates to the Subsequent Events section, no changes have been made to the previously filed audited condensed financial statements for the years ended March 31, 2024 and 2023. The accompanying notes to the Updated Financial Statements provide additional details regarding the reverse stock split and its impact on the Company's financial disclosures. EXHIBIT INDEX Exhibit No. Description 99.1 Unaudited Condensed Consolidated Financial Statements for the Three and Six Months Ended September 30, 2024 and 2023. 99.2 Management Discussion and Analysis for the Unaudited Condensed Consolidated Financial Statements for the Three and Six Months Ended September 30, 2024 and 2023. 99.3 Updated Audited Consolidated Financial Statements for the Years Ended March 31, 2024 and 2023. 99.4 Management Discussion and Analysis for the Audited Consolidated Financial Statements for the Years Ended March 31, 2024 and 2023. 99.5 Auditor's Consent for the Updated Audited Consolidated Financial Statements for the Years Ended March 31, 2024 and 2023. 101.INS Inline XBRL Instance Document. 101.SCH Inline XBRL Taxonomy Extension Schema Document. 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: January 23, 2025 Psyence Biomedical Ltd. By: /s/ Neil Maresky Name: Dr. Neil Maresky Title: Chief Executive Officer and Director

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing